Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$3.99−0.01 (-0.25%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Taysha Gene Therapies's price to sales ratio was 253.8× on Nov 11, 2026, against 205.8× a year earlier. Over the last 3 years it ranged from 26.4× to 337.5×, with a median of 77.5×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 253.8× | +15.1 |
| 2025 | Dec 31, 2025 | 238.8× | +203.0 |
| 2024 | Dec 31, 2024 | 35.8× | – |
See a number that looks wrong?